Lysyl oxidase (LOX) is a cell-secreted amine oxidase that crosslinks collagen and elastin in extracellular microenvironment. LOX-traceable nanoparticles (LOXab-NPs) consisting of LOX antibodies (LOXab) and paclitaxel, can accumulate at high concentrations at radiation-treated target sites, as a tumor-targeting drug carrier for chemotherapy. Tumor-targeting and anticancer effects of PLGA based LOXab-NPs in vitro and in vivo were evaluated at radiation-targeted site. In the in vivo A549 lung carcinoma xenograft model, we showed highly specific tumor targeting (above 7.0 times higher) of LOXab-NPs on irradiated tumors. Notably, systemically administered NPs delayed tumor growth, reducing tumor volumes by more than 2 times compared with non-irradiated groups (222% vs. >500%) over 2 weeks. Radiotropic LOXab-NPs can serve as chemotherapeutic vehicles for combined targeted chemo-radiotherapy in clinical oncology.

中文翻译：

---

电离辐射通过放射性的赖氨酰氧化酶可追踪的纳米颗粒吸引肿瘤靶向和凋亡。

赖氨酰氧化酶（LOX）是一种细胞分泌的胺氧化酶，可在细胞外微环境中交联胶原蛋白和弹性蛋白。由LOX抗体（LOXab）和紫杉醇组成的LOX可追踪纳米粒子（LOXab-NPs）可以高浓度积聚在放射治疗的靶位，作为化疗的肿瘤靶向药物载体。在辐射靶向部位评估了基于PLGA的LOXab-NP在体外和体内的肿瘤靶向和抗癌作用。在体内A549肺癌异种移植模型中，我们显示了LOXab-NP对放射肿瘤具有高度特异性的肿瘤靶向性（高7.0倍以上）。值得注意的是，与未接受辐照的组相比，全身给药的NPs在2周内使肿瘤体积减少了2倍以上（222％对> 500％）。